Matching articles for "Tramacet"
Benzhydrocodone/Acetaminophen (Apadaz) for Pain
The Medical Letter on Drugs and Therapeutics • July 15, 2019; (Issue 1576)
The FDA has approved Apadaz (KemPharm), a short-acting,
fixed-dose combination of benzhydrocodone
and acetaminophen, for short-term management
(≤14 days) of acute pain severe enough to require an
opioid...
The FDA has approved Apadaz (KemPharm), a short-acting,
fixed-dose combination of benzhydrocodone
and acetaminophen, for short-term management
(≤14 days) of acute pain severe enough to require an
opioid and for which alternative treatment options
are inadequate. Benzhydrocodone is a prodrug of
hydrocodone. Fixed-dose combinations of short-acting
hydrocodone and acetaminophen or ibuprofen
have been available for years and are the most abused
opioid products in the US. Apadaz was developed
under the presumption that inclusion of the inactive
prodrug would reduce the potential for abuse of the
combination by non-oral routes such as smoking,
snorting, or injection, but the FDA did not approve
Apadaz as an abuse-deterrent formulation.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women
The Medical Letter on Drugs and Therapeutics • May 22, 2017; (Issue 1521)
The FDA has issued new warnings about the use of the
opioid analgesics codeine and tramadol in children,
particularly those...
The FDA has issued new warnings about the use of the
opioid analgesics codeine and tramadol in children,
particularly those <12 years old, and in breastfeeding
women due to concerns about the risk of respiratory
depression and death. The FDA previously issued
warnings about these drugs in 2013 and 2015.
Another Once-Daily Formulation of Tramadol (Ryzolt)
The Medical Letter on Drugs and Therapeutics • May 17, 2010; (Issue 1338)
The FDA has approved tramadol hydrochloride extended-release (Ryzolt – Purdue) for treatment of
moderate to moderately severe chronic pain in adults. Tramadol is already available in another extended-release...
The FDA has approved tramadol hydrochloride extended-release (Ryzolt – Purdue) for treatment of
moderate to moderately severe chronic pain in adults. Tramadol is already available in another extended-release formulation (Ultram ER) and in immediate-release tablets alone (Ultram, and others) and combined with acetaminophen (Ultracet, and others).